Deepika PharmD - Pmv Pharmaceuticals Chief Officer
| PMVP Stock | USD 1.59 0.02 1.24% |
Insider
Deepika PharmD is Chief Officer of Pmv Pharmaceuticals
| Age | 47 |
| Address | 1 Research Way, Princeton, NJ, United States, 08540 |
| Phone | 609 642 6670 |
| Web | https://www.pmvpharma.com |
Pmv Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2027) % which means that it has lost $0.2027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2363) %, meaning that it created substantial loss on money invested by shareholders. Pmv Pharmaceuticals' management efficiency ratios could be used to measure how well Pmv Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.29. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Pmv Pharmaceuticals' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/26/2024, Non Current Liabilities Other is likely to grow to about 16.2 M, while Total Current Liabilities is likely to drop slightly above 9.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| RA MSc | Pharvaris BV | 43 | |
| Michael Gerometta | Opthea | 59 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| MD MBA | Opthea | N/A | |
| Nathan Dowden | Entrada Therapeutics | 53 | |
| Sarah Carmody | Vigil Neuroscience | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Wim Souverijns | Pharvaris BV | 53 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Michael Gait | PepGen | N/A | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Kyle Breidenstine | PepGen | N/A | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.2 |
Pmv Pharmaceuticals Leadership Team
Elected by the shareholders, the Pmv Pharmaceuticals' board of directors comprises two types of representatives: Pmv Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pmv. The board's role is to monitor Pmv Pharmaceuticals' management team and ensure that shareholders' interests are well served. Pmv Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pmv Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leila MD, Chief Officer | ||
| Winston MBA, COO CFO | ||
| Marc MD, Senior Affairs | ||
| Tim Smith, Senior Relations | ||
| Robert Ticktin, Head Counsel | ||
| Deepika PharmD, Chief Officer | ||
| Laura Leon, VP Operations | ||
| Crystal Zuckerman, Vice Resources | ||
| Arnold Levine, Independent CoFounder | ||
| Michael Carulli, Chief Officer | ||
| Binh Vu, Senior CMC | ||
| Thomas Shenk, CoFounder Board | ||
| David Mack, CEO, CoFounder | ||
| Robert JD, Head Counsel |
Pmv Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pmv Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (86.26 M) | ||||
| Shares Outstanding | 51.75 M | ||||
| Shares Owned By Insiders | 2.30 % | ||||
| Shares Owned By Institutions | 80.89 % | ||||
| Number Of Shares Shorted | 847.18 K | ||||
| Price To Book | 0.42 X | ||||
| EBITDA | (78.88 M) | ||||
| Net Income | (68.96 M) |
Pair Trading with Pmv Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pmv Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pmv Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Pmv Stock
| 0.69 | MTEM | Molecular Templates | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.64 | ME | 23Andme Holding | PairCorr |
| 0.6 | TPST | Tempest Therapeutics | PairCorr |
| 0.55 | AGL | agilon health Buyout Trend | PairCorr |
The ability to find closely correlated positions to Pmv Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pmv Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pmv Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pmv Pharmaceuticals to buy it.
The correlation of Pmv Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pmv Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pmv Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pmv Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.